Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.58 |
| ▸ | KIF5B | P33176 | 7/20 | 0.58 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | BLK | P51451 | 1/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.54 |
| ▸ | ADK | P55263 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 6/20 | 0.44 |
| ▸ | INSR | P06213 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441873 | 1.00 | RET (0.58) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1444354 | 1.00 | RET (0.58) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1444001 | 0.87 | RET (0.69) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1444002 | 0.87 | RET (0.69) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL27880616 | 0.85 | ADK (0.47) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL18925738 | 0.81 | ADK (0.47) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL16769694 | 0.81 | ADK (0.47) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1443270 | 0.80 | ADK (0.43) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1933318 | 0.78 | RET (0.52) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL28799602 | 0.77 | ADK (0.41) | RETKIF5BKDRKCNH2CCDC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2504339-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011064211-A1 | BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | RET 1157/4885KIF5B 2555/4885KDR 531/4885 |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | RET 853/4885KIF5B 2516/4885KDR 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.